中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

30 records (took 0.018 seconds)

    Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-) -bupropion
    1.
    发明申请
    Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-) -bupropion 审中-公开
    使用光学纯（ - ） - 安非他酮有助于戒烟和治疗疼痛和其他疾病的方法和组合物

    公开(公告)号：US20040225020A1

    公开(公告)日：2004-11-11

    申请号：US10848069

    申请日：2004-05-19

    Applicant: Sepracor Inc.

    Inventor： John R. McCullough ,  Paul D. Rubin

    IPC: A61K031/137

    CPC classification number: A61K31/137 ,  A61K31/135

    Abstract: Methods and compositions are disclosed utilizing the optically pure (null)-isomer of bupropion to assist in smoking cessation, for treating smoking and nicotine addiction, and for treating pain, including, but not limited to, chronic pain, neuropathetic pain and reflex sympathetic dystrophy, and other disorders such as narcolepsy, chronic fatigue syndrome, fibromyalgia, seasonal affective disorder and premenstrual syndrome, while avoiding adverse affects associated with racemic bupropion.

    Abstract translation: 公开了使用安非他酮的光学纯的（ - ） - 异构体来帮助戒烟，治疗吸烟和尼古丁成瘾以及治疗疼痛的方法和组合物，包括但不限于慢性疼痛，神经性疼痛和反射性交感神经营养不良 ，以及其他疾病如发作性睡病，慢性疲劳综合征，纤维肌痛，季节性情感障碍和经前期综合征，同时避免与外消旋安非他酮相关的不良影响。

    S(-)rabeprazole compositions and methods
    2.
    发明申请
    S(-)rabeprazole compositions and methods 审中-公开
    S（ - ）雷贝拉唑组合物和方法

    公开(公告)号：US20040171647A1

    公开(公告)日：2004-09-02

    申请号：US10796354

    申请日：2004-03-08

    Applicant: Sepracor Inc.

    Inventor： Patrick Koch ,  Paul D. Rubin ,  William E. Yelle

    IPC: A61K031/4439

    CPC classification number: A61K31/4439 ,  A61K31/00

    Abstract: Methods and compositions are disclosed utilizing optically pure S(null)rabeprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of rabeprazole. The optically pure S(null) isomer is also useful for the treatment of gastroesophageal reflux. S(null)rabeprazole is an inhibitor of Hnull release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

    Abstract translation: 公开了使用光学纯的S（ - ）雷贝拉唑治疗人体溃疡的方法和组合物，同时显着减少与雷贝拉唑的外消旋混合物相关的副作用的伴随的责任。 光学纯的S（ - ）异构体也可用于治疗胃食管反流。 S（ - ）雷贝拉唑是H +释放的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症，如Zollinger-Ellison综合征。

    R-hydroxynefazodone
    4.
    发明申请
    R-hydroxynefazodone 失效
    R-羟基吗唑酮

    公开(公告)号：US20020052382A1

    公开(公告)日：2002-05-02

    申请号：US09988935

    申请日：2001-11-19

    Applicant: Sepracor Inc.

    Inventor： Timothy J. Barberich ,  Paul D. Rubin ,  William E. Yelle

    IPC: A61K031/496

    CPC classification number: A61K31/496 ,  C07D249/12

    Abstract: The R-isomer of the hydroxy metabolite of nefazodone, R-hydroxynefazodone, is an effective treatment for depression which does not give rise to the adverse effects associated with nefazodone. R-hydroxynefazodone is also useful in the treatment of migraine headaches, panic disorders, post traumatic stress disorder and sleep disorders.

    Abstract translation: 奈法唑酮的羟基代谢物的R-异构体R-羟基吗啡酮是抑制剂的有效治疗剂，其不会引起与奈法唑酮相关的不良反应。 R-羟基吗唑酮也可用于治疗偏头痛，恐慌症，创伤后应激障碍和睡眠障碍。

    R-lansoprazole compositions and methods
    6.
    发明申请
    R-lansoprazole compositions and methods 审中-公开
    R-兰索拉唑组合物和方法

    公开(公告)号：US20030008903A1

    公开(公告)日：2003-01-09

    申请号：US10216962

    申请日：2002-08-12

    Applicant: Sepracor Inc.

    Inventor： Timothy J. Barberich ,  William E. Yelle ,  Paul D. Rubin

    IPC: A61K031/4439

    CPC classification number: A61K31/4439

    Abstract: Methods and compositions are disclosed utilizing optically pure (null) lansoprazole for the treatment of S ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of lansoprazole. The optically pure (null) isomer is also useful for the treatment of gastroesophageal reflux. (null) Lansoprazole is an inhibitor of Hnull release and is therefore useful in the treatment of other conditions related to gastric hypersecretion such as Zollinger-Ellison Syndrome.

    Abstract translation: 使用光学纯的（+）兰索拉唑用于治疗人类S溃疡的方法和组合物，同时显着减少与兰索拉唑的外消旋混合物相关的副作用的伴随的责任。 光学纯的（+）异构体也可用于治疗胃食管反流。 （+）兰索拉唑是H +释放的抑制剂，因此可用于治疗与胃分泌异常有关的其他病症，如Zollinger-Ellison综合征。

    Compositions for treating apnea and related disorders containing optically pure R(+) ondansetron
    10.
    发明申请
    Compositions for treating apnea and related disorders containing optically pure R(+) ondansetron 审中-公开
    用于治疗包含光学纯的R（+）昂丹司琼的呼吸暂停和相关病症的组合物

    公开(公告)号：US20040058973A1

    公开(公告)日：2004-03-25

    申请号：US10665430

    申请日：2003-09-22

    Applicant: Sepracor Inc.

    Inventor： Paul D. Rubin ,  Timothy J. Barberich

    IPC: A61K031/4178

    CPC classification number: A61K31/415 ,  A61K31/4178 ,  A61K31/00 ,  A61K2300/00

    Abstract: Methods for the treatment, management, or prevention of apnea and apnea disorders, or symptoms thereof, using a therapeutically effective amount of substantially optically pure R(null) ondansetron, or a pharmaceutically acceptable salt thereof, substantially free of its S(null) stereoisomer

    Abstract translation: 使用治疗有效量的基本上不含其S（ - ）立体异构体的基本上光学上纯的R（+）昂丹司琼或其药学上可接受的盐来治疗，管理或预防呼吸暂停和呼吸暂停障碍或其症状的方法

Patent Agency Ranking